FRANKLIN LAKES, N.J., July 11, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its recognition as a Best Place to Work for Disability Inclusion for the fifth consecutive year.
This marks BD's second consecutive year earning a top score on the Disability Equality Index® (DEI), known as the world's most comprehensive benchmarking tool to measure disability workplace inclusion. The DEI was launched in 2015 by Disability:IN and The American Association of People with Disabilities (AAPD), and was created by the DEI Advisory Committee, a diverse group of business leaders, policy experts and disability advocates.
Now in its ninth year, the DEI recognized 485 corporations for their disability inclusion efforts based on measures including culture and leadership, enterprise-wide access, employment practices, community engagement and supplier diversity, with 294 companies receiving a score of 100, including BD.
"Accelerating our efforts to drive disability inclusion by creating employment opportunities for people with diverse abilities to develop their skills and be compensated for their contributions is not only our commitment, but is a central component of our values," said Nicole Thompson, vice president of Inclusion, Diversity, Equity and Engagement for BD. "We do not see or ascribe limitations on people with disabilities. We see their capabilities and possibilities and strive to open doors to career opportunities not traditionally afforded to them. This is how we help each other be great at BD. We are honored to be recognized by Disability:IN for our ongoing and forward-thinking progress."
Limitless, one of nine company-sponsored Associate Resource Groups at BD, enables an environment of inclusion that drives innovative thinking while eliminating obstacles for those with diverse abilities. For example, Limitless members helped create a paid internship program at BD for individuals with autism. It provides participants with real-world work experience in roles that support the company's customers and patients, and help BD achieve its Purpose of Advancing the World of Health.
This recognition demonstrates the company's ongoing progress in advancing its environmental, social and governance (ESG) strategy, and efforts to achieve its 2030+ goals for promoting a healthy workforce and communities. These goals encompass maintaining a healthy and thriving workforce that cultivates the company's culture of inclusion, safety, well-being, and contributes to community and company health. In addition to this accolade, BD recently was named as a Noteworthy Company by DiversityInc in its 2023 list and was also included in the 2023 Bloomberg Gender-Equality Index (GEI) for the fourth consecutive year.
To learn more about the inclusion, diversity and equity systems, processes and tools that drive action and accountability at BD, visit the inclusion, diversity and equity pages on BD.com and read the 2022 Global ID&E Report.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
Contacts: | |
Media: | Investors: |
Troy Kirkpatrick | Francesca DeMartino |
VP, Public Relations | SVP, Head of Investor Relations |
858.617.2361 | 201.847.5743 |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$232.67 |
Daily Change: | -0.58 -0.25 |
Daily Volume: | 1,328,352 |
Market Cap: | US$67.250B |
September 03, 2024 July 25, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB